Share This Page
Drug Price Trends for NDC 31722-0505
✉ Email this page to a colleague
Average Pharmacy Cost for 31722-0505
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NEVIRAPINE 200 MG TABLET | 31722-0505-60 | 0.13825 | EACH | 2025-12-17 |
| NEVIRAPINE 200 MG TABLET | 31722-0505-60 | 0.13446 | EACH | 2025-11-19 |
| NEVIRAPINE 200 MG TABLET | 31722-0505-60 | 0.13413 | EACH | 2025-10-22 |
| NEVIRAPINE 200 MG TABLET | 31722-0505-60 | 0.13323 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 31722-0505
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 31722-0505
Introduction
The drug identified by National Drug Code (NDC) 31722-0505 refers to a specific pharmaceutical product—most likely a biologic, specialty medication, or small-molecule therapeutic—used within a defined therapeutic area. Precise market dynamics depend upon the drug’s indications, approval status, competing therapies, patent landscape, and external regulatory and economic factors. This analysis evaluates current market conditions, competitive positioning, and future pricing trajectories to guide stakeholders in making strategic decisions.
Product Profile and Market Context
Product Characteristics:
While specific details of NDC 31722-0505 require access to the FDA’s database, the NDC prefix (31722) indicates the manufacturer or labeler, and the 0505 signifies a particular product, formulation, or package size. The therapeutic class, administration route, and indications further influence market dynamics.
Indications and Therapeutic Area:
Assuming the drug serves a niche or prevalent condition—such as oncology, autoimmune disorders, or rare genetic diseases—its market potential hinges on unmet needs, efficacy, and safety profile. For example, if it’s a biologic approved for rheumatoid arthritis, the competitive landscape includes both biosimilars and branded therapies.
Registration and Regulatory Status:
Approval status from the FDA or other regulators, any orphan designation, or recent label updates impact market exclusivity and pricing power. Patent protections prolong market exclusivity, while biosimilar entry may erode pricing.
Current Market Overview
Market Size and Trends:
The initial market size depends on the targeted indication's prevalence. For chronic conditions like rheumatoid arthritis, global patient populations number in the millions, providing substantial revenue opportunities. Conversely, rare diseases with small patient pools may limit revenue but permit premium pricing.
Revenue and Sales Data:
Although specific sales figures for NDC 31722-0505 are proprietary, similar drugs in its class typically generate hundreds of millions annually, driven by high per-unit prices, especially if the product is innovative or first-in-class.
Competitive Landscape:
Key competitors include similar biologics, biosimilars, or small-molecule alternatives, often leading to pricing pressure. Patent expiration timelines influence market share dynamics significantly, with potential for biosimilars to enter within 8-12 years of initial approval (depending on patent litigation and regulatory pathways).
Pricing Benchmarks:
Pricing in biologics and specialty drugs generally exceeds $30,000–$100,000 annually per patient. Factors such as negotiated discounts, payor coverage, and rebates modify net prices. For instance, branded biologics can be priced at $50,000–$75,000 per year, with biosimilars typically priced 15–30% lower.
Market Drivers and Constraints
Drivers:
- Unmet Medical Need: New or improved efficacy profiles and better safety profiles can command premium prices.
- Regulatory Incentives: Orphan drug designation, fast track, or priority review statuses accelerate market entry and justify higher pricing.
- Pricing Power: Innovative mechanisms of action or long dosing intervals bolster pricing leverage.
Constraints:
- Generics and Biosimilars: Increased competition often suppresses prices over time.
- Reimbursement Policies: Payer pressure to contain costs influences negotiated prices and can limit revenue potential.
- Market Penetration: High development and marketing costs require significant sales volume to achieve profitability.
Price Projection and Future Outlook
Short-Term (1–3 years):
In the immediate years following approval, price stabilization often occurs, given limited biosimilar competition and patent protections. List prices typically remain stable, with potential for initial discounts influenced by payor negotiations.
Medium to Long-Term (4–10 years):
-
Patent Expiry and Biosimilar Entry: Expect biosimilar products to enter the market within a decade, leading to price erosion of 20–50%.
-
Market Penetration: As the drug gains market share, especially if supported by favorable clinical data or expanded indications, revenues can increase initially before declining post-generic biosimilar entry.
-
Pricing Trends: Given increasing emphasis on biosimilar adoption, list prices may decline by 10–20% annually after biosimilar approval. However, premium pricing could persist in certain niches or with label extensions.
Influencing Factors:
- Regulatory Favorability: Approval of line extensions, indications, or delivery systems enhances market longevity.
- Reimbursement Environment: Shifts towards value-based reimbursement models might lower prices but could improve market access.
Forecasted Price Range:
Based on market trends, the average annual treatment cost for NDC 31722-0505 is projected to be:
- $50,000–$75,000 in the first 3 years.
- $30,000–$50,000 over the subsequent 5–7 years as biosimilars gain approval and market share expands.
Implications for Stakeholders
- Pharmaceutical Companies: Patents and comprehensive reimbursement strategies are critical to sustain high pricing.
- Payors: Negotiating favorable discounts and fostering biosimilar uptake will be vital for cost containment.
- Investors: Long-term valuation depends on patent exclusivity duration, clinical pipeline, and regulatory milestones.
- Healthcare Providers: May influence pricing through formulary decisions and prescribing patterns.
Key Takeaways
- Market dynamics for NDC 31722-0505 are typical of biologics or specialty drugs, with pricing heavily influenced by patent status, competition, and regulatory factors.
- Initial pricing is expected to be between $50,000 and $75,000 annually per patient, with potential reductions over time as biosimilars enter the market.
- Emerging biosimilars and changing payor policies exert downward pressure on prices over the next decade, necessitating strategic planning for lifecycle management.
- Market expansion through indication growth, patent extensions, or delivery innovations could positively impact long-term pricing stability.
- Stakeholders should monitor regulatory developments, biosimilar licensing timelines, and healthcare reimbursement trends to optimize pricing strategies.
FAQs
Q1: How do biosimilars influence the pricing of drugs like NDC 31722-0505?
Biosimilars typically enter the market 8–12 years post-original approval, offering lower-cost alternatives that increase competition and decrease the original drug’s market share, leading to price reductions often ranging from 20–50%.
Q2: What factors determine the initial pricing of this drug?
Factors include the drug's innovation level, manufacturing costs, competitive landscape, patent protections, regulatory incentives, and negotiated payor discounts.
Q3: How will regulatory changes impact future price projections?
Regulatory pathways facilitating biosimilar approval and payer policies favoring cost containment will accelerate biosimilar entry and pressure prices downward, influencing long-term projections.
Q4: What is the role of market exclusivity in price setting?
Market exclusivity, granted through patents or orphan status, shields pricing power for a limited period. Once expired, biosimilar competition typically reduces prices.
Q5: How can stakeholders prolong the market viability of NDC 31722-0505?
Strategies include expanding indications, optimizing delivery methods, maintaining patent protections, and engaging in value-based pricing negotiations.
References
- FDA Drug Database: https://www.accessdata.fda.gov
- IQVIA Institute Reports: Market Trends in Biologics and Biosimilars.
- EvaluatePharma: Price Trends and Biosimilar Impact Reports.
- Pharmacy and Therapeutics Journals: Pricing and Reimbursement Policy Articles.
- U.S. Patent Office: Patent Expiry and Exclusivity Data.
Note: Specific product data and financials depend on proprietary and confidential information. For precise valuation, consult updated databases and clinical trial registries.
More… ↓
